Physician profile
Libby Levine
NPI 1659788990
$18,815.93
in general payments reported to CMS, 2019-2025
9 companies · $6,339 in 2025
The $6,339 reported for 2025 was more than what 98% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,448 · 2022: $86.36 · 2023: $6,773 · 2024: $3,170 · 2025: $6,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,900 · Food and Beverage: $3,598 · Honoraria: $2,400 · Travel and Lodging: $2,264 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,900.00 |
| Food and Beverage | $3,597.85 |
| Honoraria | $2,400.00 |
| Travel and Lodging | $2,263.90 |
| Education | $120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $6,574.70 | 2023-2025 | Briumvi |
| Genentech USA, INC. | $4,722.06 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Emd Serono, INC. | $2,818.92 | 2021-2025 | Mavenclad |
| Horizon Therapeutics Plc | $2,788.02 | 2023 | Uplizna |
| Biogen, INC. | $832.30 | 2023-2025 | Vumerity, Tysabri, Tysabri |
| Novartis Pharmaceuticals Corporation | $634.96 | 2021-2025 | |
| Celgene Corporation | $168.78 | 2021-2025 | Zeposia |
| Amgen INC. | $150.49 | 2025 | Uplizna |
| Genentech, INC. | $125.70 | 2025 | Ocrevus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Libby Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.